Table 1.
Characteristics of low-grade and high-grade endometrial cancer patients.
| Characteristic | Low-risk∞ (N = 925) |
High-risk∞ (N = 356) |
P value |
|---|---|---|---|
| Age at surgery (years), mean (SD) | 63.5 (11.3) | 67.3 (11.4) | <0.001 |
| BMI (kg/m2), mean (SD) | 34.4 (9.8) | 30.7 (7.8) | <0.001 |
| BMI classification | <0.001 | ||
| Underweight/normal/overweight (BMI < 30.0) | 350/924 (37.9) | 185/354 (52.3) | |
| WHO class I/II (BMI 30.0–39.9) | 336/924 (36.4) | 126/354 (35.6) | |
| WHO class III/super obese (BMI ≥ 40.0) | 238/924 (25.8) | 43/354 (12.1) | |
| Pulmonary disease† | 156 (16.9) | 54 (15.2) | 0.46 |
| Cardiovascular disease‡ | 72 (7.8) | 17 (4.8) | 0.06 |
| Diabetes | 205 (22.2) | 67 (18.8) | 0.19 |
| Smoking history | 314 (33.9) | 122 (34.3) | 0.91 |
| ASA score >2 | 367 (39.7) | 147/353 (41.6) | 0.52 |
| 2009 FIGO stage | <0.001 | ||
| Ia | 748 (80.9) | 151 (42.4) | |
| Ib or II | 101 (10.9) | 38 (10.7) | |
| IIIa, IIIb, IIIc1, or IIIc2 | 56 (6.1%) | 73 (20.5) | |
| IV | 20 (2.2) | 94 (26.4) | |
| LVSI | 75 (8.1) | 139 (39.0) | <0.001 |
| Residual disease | 4/923 (0.4) | 55 (15.4) | <0.001 |
| Primary tumor diameter >2 cm | 596/903 (66.0) | 262/344 (76.2) | <0.001 |
| Cervical stromal invasion | 28 (3.0) | 36/354 (10.2) | <0.001 |
| Myometrial invasion (%), median (IQR) | 12.0 (3.7, 33.3) | 25.0 (8.7, 71.4) | <0.001 |
| Gross extrauterine disease | 16 (1.7) | 73 (20.5) | <0.001 |
| Adnexal involvement | 19 (2.1) | 80 (22.5) | <0.001 |
| Serosal involvement | 13 (1.4) | 67 (18.8) | <0.001 |
| Positive peritoneal cytology | 77/788 (9.8) | 108/335 (32.2) | <0.001 |
| Laparotomy | 763 (82.5) | 336 (94.4) | <0.001 |
| Pelvic nodes removed, median (IQR) | 18 (0, 35) | 29 (19, 38) | <0.001 |
| Paraaortic nodes removed, median (IQR) | 0 (0, 13) | 10 (0, 17) | <0.001 |
| Pelvic lymph node status | <0.001 | ||
| No LND or inadequate/negative LND | 411 (44.4) | 63 (17.7) | |
| Adequate/negative LND | 467 (50.5) | 201 (56.5) | |
| Positive pelvic nodes | 47 (5.1) | 92 (25.8) | |
| Paraaortic lymph node status | <0.001 | ||
| No LND or inadequate/negative LND | 555 (60.0) | 118 (33.2) | |
| Adequate/negative LND | 343 (37.1) | 177 (49.7) | |
| Positive para-aortic nodes | 27 (2.9) | 61 (17.1) | |
| Adjuvant therapy | <0.001 | ||
| No adjuvant therapy | 722/892 (80.9) | 97/323 (30.0) | |
| Vaginal BT or EBRT ± BT | 121/892 (13.6) | 98/323 (30.3) | |
| Chemo ± BT or chemo and EBRT ± BT | 49/892 (5.5) | 128/323 (39.6) | |
| 30-day postoperative complications | <0.001 | ||
| None or grade 1 | 721 (77.9) | 215 (60.4) | |
| Grade 2 or 3 | 183 (19.8) | 125 (35.1) | |
| Grade 4, 5, or 6 | 21 (2.3) | 16 (4.5) |
Abbreviations: LND, lymphadenectomy; FIGO, International Federation of Gynecology and Obstetrics; ASA, American Society of Anesthesiologists, PA, para-aortic; EBRT, external beam radiotherapy; BT, brachytherapy.
Pulmonary disease is defined as a report of at least one of the following: dyspnea, history of severe chronic obstruction pulmonary disease (COPD), current pneumonia, history of sleep apnea, or past/current CPAP use.
Cardiovascular disease is defined as a report of at least one of the following: congestive heart failure (CHF) within 30days, history of myocardial infarction (MI) within 6months, previous cardiac stenting, previous cardiac surgery, history of angina within 30days, history of revascularization/amputation for peripheral vascular disease (PVD), or rest pain/gangrene.